Robotic surgery for advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of robotic-assisted surgery using the Vessel Sealer Extend for patients with locally advanced gastric cancer. The Da Vinci robotic system enhances surgical precision through 3D magnification and improved instrument flexibility, addressing limitations of traditional laparoscopic techniques. The study aims to assess outcomes such as blood loss, hospital stay duration, and lymph node dissection effectiveness in patients undergoing robotic gastrectomy. It focuses on patients with specific stages of gastric adenocarcinoma who meet defined eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age from over 18 to under 75 years
* Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
* cT2-4a, N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
* Preoperative abdominal enhanced CT and lung CT (or PET-CT) showed no distant metastasis
* Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale
* ASA (American Society of Anesthesiology) class I to III
* Written informed consent

Exclusion Criteria:

* Gastric multiple primary carcinoma or multiple primary cancer
* History of previous upper abdominal surgery (except laparoscopic cholecystectomy)
* History of previous gastric surgery (except ESD/EMR (Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection ) for gastric cancer)
* Preoperative gastric CT evaluation and chest and abdominal imaging evaluation were not performed before surgery, and the clinical stage of the tumor was not comprehensively evaluated
* Enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative imaging
* History of other malignant disease within the past 5 years
* History of previous neoadjuvant chemotherapy or radiotherapy
* History of unstable angina or myocardial infarction within the past 6 months
* History of cerebrovascular accident within the past 6 months
* History of continuous systematic administration of corticosteroids within 1 month
* FEV1\<50% of the predicted values
* Women during pregnancy or breast-feeding
* Severe mental disorder
* Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
* Preoperative evaluation requires combined organ resection
* Requirement of simultaneous surgery for other disease

Where it's running

• First Hospital of Jilin University
  Changchun, Jilin, China Recruiting

Study contacts

• Study coordinator: Quan Wang, Professor
• Email: wquan@jlu.edu.cn
• Phone: +86 15843073207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HIPEC-primed therapy with serplulimab plus SOX/XELOX for locally advanced gastric cancer

  This study tests a HIPEC-priming approach followed by PD-1 blocker–based chemotherapy to see if it helps people with locally advanced gastric cancer who have not yet spread.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07621484

• Personalized ultrafractionated radiation plus immunotherapy for unresectable stomach cancer

  This study tests, in patients with unresectable locally advanced stomach cancer who have not progressed after initial therapy, whether adding PULSAR radiation to ongoing systemic treatment improves control of the tumor.

  Recruiting Samsung Medical Center · Seoul, Select Province/State · NCT07607119

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• Neoadjuvant immunotherapy plus Nab-P-SOX for locally advanced gastric/GEJ cancer

  This phase 2, single-arm study tests a pre-surgery treatment that combines a PD-1/CTLA-4 bispecific antibody with nab-paclitaxel, oxaliplatin, and S-1 in adults with HER2-negative, locally advanced gastric or GEJ cancer.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07867392

• Maintenance therapy in metastatic gastric cancer: a multicenter look from Colombia

  This study reviews medical records of adults with metastatic gastric cancer in Colombia to see how patients fare after starting maintenance therapy following initial chemotherapy.

  Recruiting at 4 sites Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. and 3 other locations · NCT07856212

• AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer

  Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.

  Recruiting Hebei Medical University · Shijiazhuang, None Selected · NCT07849608

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.